Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

437 recalls, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 20262025202420232022 All years
Cause Sterility / contaminationNitrosamine impurityChemical / undeclaredParticulate / foreign matterLabeling / mix-upcGMP deviationMicrobial contamination All causes
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-330-03 D-0413-2019
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-331-09 D-0412-2019
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-331-03 D-0411-2019
Class II · Moderate risk

Irbesartan and HydrochlorothiazideTablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-330-09 D-0410-2019
Class II · Moderate risk

Irbesartan Tablets 300 mg 90 count Rx only Manufactured by…

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-376-09 D-0409-2019
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-748-90 D-1116-2018
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-747-90 D-1115-2018
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-746-90 D-1114-2018
Class II · Moderate risk

Camber Pharmaceuticals

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Completed Nitrosamine impurity Hetero Labs Limited Unit V NDC 31722-745-30 D-1113-2018
Class III · Low risk

Remeven Cream

Crystallization; Complaints that cream appears to have crystallized

Completed Failed specification Stratus Pharmaceuticals Inc D-1464-2016
Class II · Moderate risk

Sterile Water for Injection

Marketed Without An Approved NDA/ANDA: Product is sold over the counter whose labeling indicates it is to be used for parenteral injection.

Completed Unapproved drug Flawless Beauty LLC D-1321-2014
Class II · Moderate risk

Vitamin C (ascorbic acid)

Marketed Without An Approved NDA/ANDA: Parenteral product is sold over the counter whose labeling indicates it is to be used for the treatment of disease.

Completed Unapproved drug Flawless Beauty LLC D-1320-2014
Class II · Moderate risk

Relumins Advanced Glutathione

Marketed Without An Approved NDA/ANDA: Product is sold over the counter whose labeling indicates it is to be used parenterally for drug claims.

Completed Unapproved drug Flawless Beauty LLC D-1319-2014
Class II · Moderate risk

Saluta (reduced glutathione)

Marketed Without An Approved NDA/ANDA: Parenteral product is labeled for use as an antidote.

Completed Unapproved drug Flawless Beauty LLC D-1318-2014
Class II · Moderate risk

Laroscorbine Platinium

Marketed Without An Approved NDA/ANDA: Product is sold over the counter whose labeling includes drug claims to act as an antidote.

Completed Unapproved drug Flawless Beauty LLC D-1316-2014

Recalls by year